ABSTRACT D-Lysergic acid diethylamide and D-2-bromolysergic acid diethylamide are competitive antagonists of the histamine activation of adenylate cyclase [ATP pyrophosphate-lyase (cyclizing); E.C. 4.6.1.11 in broken cell preparations of the hippocampus and cortex of guinea pig brain. The adenylate cyclase is linked to the histamine H2-receptor. Both Dlysergic acid diethylamide and D-2-bromolysergic acid diethylamide show topological congruency with potent H2-antagonists. D-2-Bromolysergic acid diethylamide is 10 times more potent as an H2-antagonist than cimetidine, which has been the most potent H2-antagonist reported, and D-lysergic acid diethylamide is about equipotent to cimetidine. Blockade of H2-receptors could contribute to the behavioral effects of D-2-bromolysergic acid diethylamide and D-lysergic acid diethylamide.
Evidence is growing that histamine may function as a neurotransmitter (see reviews, refs. 1-4). Histamine has a nonuniform regional distribution in brain. Most of the histamine is found in subcellular fractions containing nerve endings. Brain contains specific enzymes for histamine formation and metabolism. Histamine appears to turn over rapidly. Potassium ions release histamine from brain slices by a calcium-dependent process. Brain lesions result in a fall in the activity of histidine decarboxylase in areas distal to the lesion. Neurons respond to histamine. Histamine stimulates the activity of adenylate cyclase JATP pyrophosphate-lyase (cyclizing); EC 4.6.1.1] and this effect is blocked by histamine HI-antagonists (5, 6) and histamine H2-antagonists (6, 7) . We show here that D-lysergic acid diethylamide (D-LSD) and D-2-bromo-LSD (D-BrLSD) are competitive antagonists of histamine in the activation of the H2-receptor linked to adenylate cyclase in the hippocampus arid cortex of the brain.
MATERIALS AND METHODS Preparation of Tissue. Membrane-bound adenylate cyclase was prepared from brain by homogenization in a Potter-Elvejhem glass-Teflon vessel in 0.32 M sucrose/5 mM Tris-HCl/1 mM ethylene glycol bis(3-aminoethyl ether)-N,N'-tetraacetate (EGTA)/1 mM dithiothreitol pH 7.4. The homogenate was centrifuged at 1000 X g and the supernatant fraction was centrifuged again at 27,000 X g. The pellet from the second centrifugation was washed twice by resuspension in the same medium and collected by centrifugation. The final pellet was suspended in the same medium at a protein concentration of 0.5-0.7 mg/mi. The membranes could be quickly frozen with dry ice/acetone and stored at -70°. Freezing and storage invariably resulted in an increase in basal activity and a decrease in maximal histamine activation, but the agonist potencies (ED50; amount necessary to produce half-maximal response) and antagonist affinities (pA2) were not altered.
Adenylate Cyclase Assay. The assay system has been described (8) . All assays were performed in triplicate. All additions were made to the assay tubes on ice. They were then transferred to a 30°shaking incubator and preincubated for 5 min to allow the enzymatic activity to reach a steady state and to eliminate the influence of any lag periods in hormone activation. After the preincubation period, 25 pl of [a-32PJATP (1-2 gCi) were added and in most cases the reaction was allowed to proceed for 10 min, when it was stopped by adding 100 ,il of 1% sodium dodecyl sulfate. After addition of 650 gl of [3H]cyclic AMP (13H]cAMP; 5000-10,000 cpm) to monitor recovery, the labeled cAMP was isolated with an alumina and Dowex column (9) . The reaction was linear with protein concentration (10) considerable H2-agonist activity but with less than 0.0001% of the activity of histamine on HI-receptors (13), was active in the same concentration range as was histamine.
Although measuring the relative potencies of agonists has been useful in classifying histamine receptors (14) , these measurements are not dependable tools: the potencies of dimaprit and other agonists (13, 15) can vary 50-fold relative to histamine on different H2-receptors. More persuasive evidence for defining receptors comes from studies of antagonists (14) . Fig. 1 shows typical dose-response curves for the effect of histamine on guinea pig hippocampal adenylate cyclase activity in the presence and absence of different concentrations of the H2-antagonist, cimetidine. Cimetidine caused a parallel shift in the dose-response curve. Also shown in Fig. 1 (16, 19, 20) on H2-receptors in other organs (Table 2) .
At high concentration, the HI-antagonists (mepyramine and tripellenamine) also blocked the histamine-activation of hippocampal adenylate cyclase activity. The pA2 values of these antagonists on histamine-activated adenylate cyclase differed markedly from the pA2 values on the HI-receptor (Table 2 ). These differences provide evidence thait in blocking histamine-activation of the cyclase in the hippocampus, the H1-antagonists are not acting on HI-receptors. Importantly, the activation of the cvclase by dimaprit, a compound virtually devoid of HI-activity, was also blocked by HI-antagonists. On the hippocampal enzyme, the pA2 value of mepyramine with histamine as agonist was 5.18 (Table 2) ; with dimaprit as agonist on two preparations, the pA2 value was not significantly different, 5.04. These findings suggest that at these high concentrations the HI-antagonists block the H2-receptor.
We compared, on the hippocampus from two guinea pigs, the effects of histamine, norepinephrine, isoproterenol, and dopamine in the activation of adenylate cyclase. (Fig. 2) . The Schild plot (Fig. 2) Unlike others (7), we found that adenylate cyclase in the rat hippocampal homogenates was also stimulated by histamine (Table 1) . Our assay medium differed in containing dithiothreitol, cAMP, a system to generate ATP, theophylline (4 mM) instead of 3-isobutyl-1-methylxanthine (1 mM), half the concentration of EGTA, 10-5 M of GTP rather than 10-4 M, and a slightly lower pH (7.4 rather than 7.8); the basal activity in our experiments on rats was about one-third that found by others (7) . Activation by histamine of adenylate cyclase in the rat hippocampus was less than that in guinea pig hippocampus, in accord with the relative insensitivity of rats to many effects of histamine (24) .
The histamine-stimulated adenylate cyclase in broken cell preparations of the hippocampus of the guinea pig is linked to an H2-receptor, as previously shown (7). The H2-antagonist competitively blocked this effect of histamine, shifting the dose-response curve in a parallel manner, as shown for cimetidine (Fig. 1) . Dimaprit, an H2-agonist with almost no HIactivity (13) , activated the cyclase, and cimetidine blocked this effect of dimaprit. The unit slope of the Schild plot for cimetidine, with either histamine or dimaprit as agonist (Fig. 1) , implies simple competition (12) . The pA2 values of a series of known H2-antagonists in inhibiting the histamine-or dimaprit-activated cyclase are the same as the pA2 values on known H2-systems (Table 2 )-the histamine receptor linked to atrial rate, uterine relaxation, and gastric acid secretion (16) (17) (18) (19) (20) . All of these were classified as H2-systems mainly because the pA2 values of H2-antagonists were very nearly the same on all three preparations (14) .
The HI-antagonists also blocked histamine-activated cyclase, shifting the dose-response curves in a parallel manner. However, the pA2 values on the histamine-linked cyclase were low, i.e., the concentration of HI-antagonist needed to block this effect was far higher than that needed to block the HI-receptor in the guinea pig ileum ( Table 2) . At these concentrations, the HI-antagonists are therefore not acting on the HI-receptor but rather on another one, almost certainly the H2-receptor: only an H2-receptor could be shown in these broken cell preparations (ref. 7 ; Table 2 ), and second, mepyramine blocked the activation by dimaprit, which is almost exclusively an H2-agonist.
In many previous studies of histamine activation of adenylate cyclase, notably those on brain slices, both HI-and H2-antagonists-were observed to block the effect of histamine in stimulating adenylate cyclase activity. These observations prompted the conclusion that both HI-and H2-receptors mediate the stimulation. The HI-receptor may be active in slices and not in broken cell preparations. However, in many of the experiments on brain slices, only one concentration of antagonist was used and in none were the antagonist affinities estimated to compare with their affinities for well-defined H1-and H2-receptors. Histamine and Pharmacology of D-LSD and BrLSD. D-LSD is a competitive antagonist of histamine at the H2-receptor. The pA2 value of D-LSD was 5.95, very nearly that of cimetidine, 6.22, and of metiamide, 6.06, the two potent H2-antagonists. The L-isomer, which has no measurable central effects, did not antagonize the histamine-activated adenylate cyclase. BrLSD (pA2 = 7.16) was about 10 times more potent than D-LSD in inhibiting histamine-stimulated adenylate cyclase activity.
BrLSD is active, though less potent than D-LSD, on many behavioral (25, 26) and electrophysiological (27, 28) systems, but it has about the same affinities as does D-LSD for the high-affinity binding sites for D-LSD (29, 30) and a greater affinity for the haloperidol binding sites (31) . BrLSD was also more potent than D-LSD in increasing levels of dopa (32) and a dopamine metabolite, 3,4-dihydroxyphenylacetic acid (33) , in rat striatum. Thus, agonist activity of BrLSD at dopaminergic (26) and serotonergic (27) sites is less than that of D-LSD but the antagonist activity at dopaminergic sites appears to be greater than that of D-LSD (31) (32) (33) . Further evidence that D-LSD and BrLSD have affinities for the same receptors is that BrLSD blocks the effect of D-LSD on isolated tissue (34) and its behavioral effect in mice (35) . Some of the receptors for which BrLSD has affinity are likely to be implicated in the hallucinations produced by D-LSD, for BrLSD blocks the hallucinogenic effect of D-LSD (36) (37) (38) . BrLSD does not produce hallucinations but it causes other psychic effects qualitatively the same as LSD, including confusion, sensations of unreality, and depersonalization (38) (39) (40) .
Antagonism of H2-receptors could contribute to the central and other pharmacological effects of D-LSD and BrLSD. The affinities of histamine antagonists for the histamine receptor linked to adenylate cyclase are strikingly similar to their affinities for physiologically functioning receptors (Table 2 ). This agreement suggests that the action of other drugs on the cyclase reflects these physiological effects. Experiments in different species show that the concentration of D-LSD in brain may be suifficient to occupy some of the H2-receptors. In laboratory animals (25-28, 32, 33, 35) , larger doses of D-LSD are required to elicit central effects than are needed in human beings (,6-42) . In rats (43) [as in cats (44) (45, 46) . Guinea pigs require a dose 5-12 times higher than do rats to exhibit a similar behavioral response (47) , and the measured KB of D-LSD for the histamine receptor is 1.1 AM. In addition, D-LSD is concentrated in the hippocampus both in monkeys (48) and rats (49) . The hippocampal concentration, measured in monkeys (48) after the administration of 0.5 mg of D-LSD/kg of body weight, was 0.39 ,g/g or 1.3 ,mol/kg, which is greater than the apparent KB for occupying the H2-receptor linked to adenylate cyclase.
The hippocampus as a site of interaction of histamine and D-LSD may have special importance. D-LSD and lesions of the hippocampus produce similar effects. Both enhance some types of perseveration (50, 51) and both interfere with some kinds of habituation, e.g., after these treatments an animal responds to a stimulus to which it had previously been refractory (51) (52) (53) (54) shown by biochemical studies (29-33, 61) noted above; early electrophysiological studies showed that LSD affects more than one central receptor (62) .
D-LSD and H2-blockers have some common structural characteristics, as shown for metiamide (Fig. 3) . 
